Redcare Pharmacy H1 Loss Narrows; Backs FY25 Outlook

Redcare Pharmacy N.V. (RDC.DE) reported a significantly narrower first-half net loss of €2.76 million, down from €12.97 million year-over-year, driven by robust 27% sales growth to €1.43 billion across all divisions. The second quarter also saw improved results, including a net income of €8.9 million boosted by a €14.2 million one-off gain from convertible bond transactions. The company reiterated its fiscal 2025 outlook for over 25% sales growth and an adjusted EBITDA margin of 2-2.5%, affirming confidence in its path to profitability and a longer-term adjusted EBITDA margin exceeding 8%.

Analysis

Redcare Pharmacy N.V. demonstrated strong top-line momentum in its first-half results, with a 27% year-over-year increase in sales to €1.43 billion, driven by growth across both prescription and non-prescription segments. This robust sales performance significantly narrowed the net loss to €2.76 million from €12.97 million in the prior-year period. However, profitability improvement was more subdued, as adjusted EBITDA for the first half only increased marginally to €27.2 million from €26.8 million. The reported second-quarter net income of €8.9 million is primarily attributable to a one-off positive impact of €14.2 million from convertible bond transactions, which masks an underlying operational loss for the quarter. The company’s decision to reaffirm its fiscal 2025 guidance for sales growth above 25% and an adjusted EBITDA margin of 2-2.5%, alongside its long-term target of exceeding an 8% margin, signals strong management confidence in its growth trajectory and path to profitability.

Key Decisions for Investors

• The consistent 27% revenue growth and reaffirmed guidance support a positive outlook for investors prioritizing top-line expansion and market share consolidation in the online pharmacy sector.
• Investors should scrutinize future reports for organic margin improvement, recognizing that the reported Q2 net profit was driven by a one-off financial transaction rather than core operational profitability.
• The ability to meet the fiscal 2025 adjusted EBITDA margin target of 2-2.5% will serve as a critical validation point for management's credibility and the company's long-term plan to achieve a margin exceeding 8%.